Skip to main content

CannTrust To Be Delisted From NYSE And TSE

CannTrust To Be Delisted From NYSE And TSECanadian cannabis company CannTrust Holdings Inc. (NYSE: CTST) (TSE:TRST) has acceded to creditor protection under CCAA.Trading of CannTrust has been stopped on the Toronto Stock Exchange and in New York. The company is expected to be delisted from both exchanges as a result of filing the for creditor protection.CannTrust stated that this decision was taken in order to preserve the companies best interest."While today's news was a foregone conclusion, in my view, it is a stark reminder of how this industry and its actors are beholden to higher standards than most consumer product categories," Matt Markiewicz, Managing Director of Innovation Shares, which is behind the Cannabis ETF (NYSE: THCX), told Benzinga. "There should be no gray area when compliance is involved and CannTrust, along with its investors, have now paid a heavy price for violating Health Canada's rules."See Also: How Legalizing Cannabis Could Ease Government Shortfalls Once Coronavirus Pandemic Is OverAlthough the company had dropped the stock from the THCX portfolio in August 2019, the damage to U.S. investor confidence has persisted, Markiewicz explained."A lot of that has to do with the fact that this was one of the more visible publicly-traded cannabis stocks especially after its high profile equity offering in May 2019," he said. "With any nascent industry you expect several bumps in the road but hopefully they are not too costly from an investment perspective."See more from Benzinga * Cannabis Stock Gainers And Losers From March 25, 2020 * Cannabis Stock Gainers And Losers From March 19, 2020 * Cannabis Stock Gainers And Losers From March 18, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.




from Yahoo Finance https://ift.tt/2JszEnt

Comments

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 billion, or $

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected may be